Abstract
Neurological diseases, including Alzheimer's disease, Parkinson's disease, and glioblastoma, present unique challenges to effective pharmacological treatment due to the selective permeability of the blood-brain barrier (BBB). Recent advancements in drug delivery systems (DDS) offer promising solutions to enhance brain-targeted therapy. Nanocarriers, intranasal delivery, and focused ultrasound-mediated delivery are among the innovative approaches reshaping the treatment landscape. This article reviews the latest progress in DDS for neurological disorders, focusing on their mechanisms, advantages, and clinical applicability. These technologies represent a paradigm shift toward more efficient, targeted, and personalized neuropharmacology.
All articles published in the American Journal of Pharmacy and Pharmacology are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows others to:
-
Share — copy and redistribute the material in any medium or format
-
Adapt — remix, transform, and build upon the material for any purpose, even commercially
Under the following terms:
-
Attribution — Appropriate credit must be given to the original author(s) and source, a link to the license must be provided, and any changes made must be indicated.
By submitting their work, authors agree to these licensing terms and retain copyright of their articles.